Clinical Trial Update: STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is evaluating the combination of stereotactic body radiotherapy and Lutetium-177 PSMA-617 for locally advanced prostate cancer. The study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Angela Y. Jia, MD PhD | Conditions: Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING